We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients Product Name:Leuprorelin CAS No.:53714-56-0 Standard:ChP, USP, EP Price(USD):Negotiable Company:HYBIO PHARMACEUTICAL CO., LTD.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East
Sample Provided: no
Payment Terms: T/T
Indications:
Advanced prostate cancer
Endometriosis
Central precocious puberty
Uterine fibroids
Some cases of infertility
Mechanism of Action: Leuprorelin acts as an agonist at pituitary GnRH receptors. With continuous administration, it initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, with chronic use, it suppresses these hormones, leading to decreased testosterone in males and decreased estrogen in females.
Pharmacokinetics:
Absorption: Depends on the formulation. Long-acting forms are developed to slowly release the drug.
Distribution: Distributed widely in the body.
Metabolism: Minimal metabolism, with the majority of the drug remaining intact.
Excretion: Excreted primarily through the kidneys.
Form: Leuprorelin API is usually available as a white to off-white powder.
Sixteen years of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
